ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Microbiome specialist Arranta Bio raises $82 million

by Marc S. Reisch
November 9, 2019 | APPEARED IN VOLUME 97, ISSUE 44

 

Arranta Bio, a 6-month-old contract development and manufacturing organization, has raised $82 million from investors including Thermo Fisher Scientific and the private equity firm Ampersand Capital Partners. Arranta plans to develop and commercialize therapies for customers targeting diseases linked to the human microbiome. It expects to open late-clinical and commercial-ready capacity in Watertown, Massachusetts, by mid-2020. Separately, Arranta has formed a partnership in which it will provide Thermo Fisher with gene therapy materials.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment